Castle Biosciences says prospective study shows low-risk DecisionDx-Melanoma results link to 4.4% SLN positivity, 99.6% five-year RFS without SLNB

Bitget2026/09/30 20:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Castle Biosciences will present late-breaking EADV 2026 data on DecisionDx-Melanoma on Oct. 1 in Vienna.
The prospective, multicenter study supports using the test to help some melanoma patients skip sentinel lymph node biopsy.
Outcomes also back using the assay to flag early-stage patients who may need closer post-surgical surveillance.
Separate EADV ePoster data indicate the test can clarify recurrence risk when biopsy-based staging is uncertain due to transected tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA60742) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Castle Biosciences says prospective study shows low-risk DecisionDx-Melanoma results link to 4.4% SLN positivity, 99.6% five-year RFS without SLNB

You may also like

Crypto prices